Cell line · CVCL_0528
Papers56
1 to 20 of 56
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PP2A Activation as a Senotherapeutic in Neuroblastoma. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Irinotecan Modulates Immune Checkpoints in Neuroblastoma. | Immunotargets Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NDUFS6 promotes neuroblastoma progression and represents a potential therapeutic target. | Transl Pediatr | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 45A ncRNA Expression Leads to Chromosomal Instability and Cytoskeletal Dynamics Impairment by Modulating GTSE1/p53/AurB Subcellular Localization. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi‑omics identification of MSI2 as a super-enhancer‑driven vulnerability in MYCN‑amplified neuroblastoma. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| QW-5-70 Targets the Colchicine Site and Demonstrates Antitumor Activity in P-gp-Overexpressing Cancer Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. | Clin Transl Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| POLQ mediated end-joining promotes DNA damage tolerance in neuroblastoma. | Transl Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral γδT-cell Activity. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cell types or cell states? An investigation of adrenergic and mesenchymal cell phenotypes in neuroblastoma. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma. | EMBO J | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A disease-associated PPP2R3C-MAP3K1 phospho-regulatory module controls centrosome function. | Curr Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Cas9 screening develops an epigenetic and transcriptional gene signature for risk stratification and target prediction in neuroblastoma. | Front Cell Dev Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0528/papers